Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
-
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
-
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
-
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
-
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
-
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results
-
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
-
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
-
IN8bio to Present at Upcoming Investor and Scientific Conferences in February